Skip to main content
Fig. 1 | BMC Pharmacology and Toxicology

Fig. 1

From: A pharmacovigilance study of olanzapine/samidorphan based on FDA Adverse Event Reporting System (FAERS)

Fig. 1

Disproportional analysis of adverse events (AEs) in olanzapine/samidorphan. (A) Bar plot illustrates the number of adverse eventsassociated with the olanzapine/samidorphan combination. (B) The displays the log(ROR) and 95% confidence intervals (CIs) for adverse events (AEs) associated with the olanzapine/samidorphan combination. A lower bound of the ROR 95% confidence interval greater than 1 is represented in deep purple, while a lower bound that does not exceed 1 is shown in light purple

Back to article page

BMC Pharmacology and Toxicology

ISSN: 2050-6511

Contact us